Investigational Therapy, Tucatinib, Shows Early Promise for HER2-positive Patients
News
Findings from a Phase 1 clinical trial show that women with heavily treated breast cancer could benefit from the investigational HER2 small molecule inhibitor tucatinib. Despite a median of five ... Read more